Objective: Significant weight gain is a problematic side effect of treatment with the antipsychotic drug olanzapine (OLA). Previous studies in rats suggest that one of the contributing factors is an impairment in satiation that results in increased food intake. However, the mechanisms underlying this impairment in satiation remain largely unclear. Methods and results: In this study, we determined the effect of OLA on levels of leptin, insulin, ghrelin, cholecystokinin (CCK), glucagon-like peptide-1, peptide YY and amylin in male rats that had received a fixed amount of food. OLA did not affect the secretion of any of these hormones, except for ghrelin levels, which were increased compared with controls. Furthermore, when ghrelin levels were determined in rats just before they received their meal, OLA caused a significant increase in ghrelin levels compared with controls, whereas OLA failed to affect baseline ghrelin levels. Next, we investigated the effect of OLA on the efficacy of CCK to reduce meal size. With coadministration, OLA pretreatment counteracted the reduction in meal size by CCK, although there was no significant interaction between the treatments. Finally, telemetry measurements revealed that acute OLA treatment causes a temporary decrease in both locomotor activity and body core temperature. Conclusion: Taken together, this study shows that acute injection of OLA selectively increases meal-related ghrelin secretion and this may partially underlie the impairment in satiation by OLA.
Introduction
The introduction of second-generation antipsychotic drugs, such as olanzapine (OLA), has significantly improved the treatment outcome of several psychiatric illnesses, including schizophrenia and bipolar disorder. [1] [2] [3] [4] OLA is one of the drugs considered superior to conventional antipsychotics, because of reduced extrapyramidal side effects as well as improvement of negative symptoms. 1,2 Unfortunately, second-generation antipsychotics have been associated with several metabolic side effects and significant weight gain is especially observed in patients treated with OLA. 5, 6 The mechanisms underlying antipsychotic-induced weight gain remain largely unclear. However, several clinical studies suggest that altered eating behavior is an important contributing factor: patients treated with atypical antipsychotics such as OLA frequently report an increase in appetite, appear more susceptible to hunger and experience ingested food as less satiating. [7] [8] [9] [10] The regulation of appetite and eating behavior is determined by a complex interaction of different systems. The brain receives information about adiposity levels through circulating factors, such as insulin and leptin, and signals from the gastro-intestinal tract through vagal afferents and gut-derived hormones, such as ghrelin, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1). These signals are integrated with input from brain areas that convey the sensory and rewarding aspects of food, and ultimately result in either initiation or termination of a meal. 11, 12 Which components of this process are influenced by antipsychotic drugs such as OLA remains largely unclear. Several rodent studies, including our own, suggest that OLA affects food intake by impairing the satiation process, which manifests itself by an increase in meal size or shortterm food intake. [13] [14] [15] [16] This impaired satiation may be due to an effect of OLA on the secretion of satiety and/or satiation factors, but it could also be due to a reduction in sensitivity to these factors. To investigate whether OLA influences food intake through effects on the secretion of gastro-intestinal peptides that are released in response to a meal, we determined the effects of an acute injection of OLA on levels of several hormones that are known to have a role in food intake, namely leptin, insulin, ghrelin, CCK, PYY, GLP-1 and amylin. 12 This revealed an increase in periprandial levels of the orexigenic hormone ghrelin in OLA-treated rats. Administration of ghrelin directly into the brain has previously been associated with a more marked increase in meal frequency than in meal size. 17, 18 This seems to be in contrast with the meal patterns of olanzapine-treated rats, which exhibit an increase in meal size accompanied by a compensatory decrease in meal frequency. 14, 16 However, peripheral administration of exogenous ghrelin prior to a buffet-style meal has been shown to increase subsequent caloric intake in humans. 19 Furthermore, peripherally administered ghrelin affects meal size in rodents as well, depending on the experimental circumstances. 20, 21 This effect on meal size may be explained by the finding that pretreatment with ghrelin was able to completely abolish the effect of CCK on food intake, an effect that seems to be due to ghrelin preventing the activation of vagal nerves by subsequent CCK administration. 22 As the meal patterns of OLA-treated rats markedly resemble those of rodents lacking the CCK-1 receptor 23 and ghrelin has a role in CCK sensitivity, 22 we hypothesized that OLA might reduce the sensitivity to endogenously released CCK in response to a meal.
To test this hypothesis, we investigated the effect of OLA pretreatment on the efficacy of CCK to reduce meal size in male rats. In this behavioral paradigm, OLA was administered acutely to enable repeated measurements in individual animals. In our previous study, OLA was administered continuously and it affected not only meal size but also locomotor activity and body core temperature. 16 Therefore, these parameters were also monitored in the present study, in order to compare the results of acute administration with previous findings.
Materials and methods

Animals
Male Wistar rats, weighing 275-300 g, were purchased from Charles River Laboratories (Crl-Wu, Sulzfeld, Germany). anesthesia. In addition, an i.p. canula was implanted to administer drugs painlessly. This canula consisted of a silicon tubing (S0.6 Â 1.2D, Raumedic, Helmbrechts, Germany), B20 cm in length, of which the proximal end was positioned intra-abdominally. The intra-abdominal part consisted of approximately 4 cm of tubing that had been perforated at regular intervals to prevent blockage. The distal end was tunneled subcutaneously (s.c.) and attached to a connector pedestal (313-000, Plastics One, Roanoke, VA, USA) that was fixed to the skull using dental cement and screws. Immediately after placement of the canula, it was flushed with saline (1 ml kg
À1
) to remove any debris and a dust cap placed on the tip of the connector pedestal. Additionally, cannulas were flushed with saline on the first postoperative day, and at least twice weekly throughout the experiment to prevent blockage. Carprofen (Rimadyl, Pfizer Animal Health, Capelle a/d IJssel, The Netherlands, 0.5 mg per 100 g s.c.) was administered as pain medication preoperatively and once daily postoperatively for 2 days. Animals were allowed to recover for 2 weeks before the first drug administration.
Drugs OLA (Chempacific Corp., Baltimore, MD, USA) was dissolved in a minimum quantity of 1 M hydrochloric acid and diluted with saline. If necessary, 1 M sodium hydroxide was used to adjust the pH to B5.5. A stock solution of 4 mg ml À1 was made at the start of the experiment, this solution was aliquoted, stored at À20 1C and used during the experiment to prepare fresh solutions by diluting with saline as needed. Similarly, a stock solution (50 mg ml
) of CCK octapeptide (sulfated) ammonium salt (Bachem AG, Bubendorf, Switzerland) was prepared using phosphate buffered saline (PBS), stored in aliquots at À20 1C and diluted with PBS on test days.
Olanzapine's effects on meal-related ghrelin and CCK EM van der Zwaal et al The dose of OLA was chosen based on the fact that acute administration of 1 mg kg À1 OLA in rats results in peak receptor occupancy levels that are comparable to humans. 24 The dose of CCK was chosen based on a pilot experiment that indicated this was the minimum effective dose to reduce meal size in our paradigm.
Experimental designs
Experiment 1
To determine the effects of acute OLA administration on the secretion of different meal-related hormones, we used three different setups. In each case, rats had been used in a different set of acute pharmacological experiments previously, but had gone through a wash-out period of at least 2 weeks. During this time, food intake and body weight gain were also monitored so that, for each experiment, treatment groups could be matched for both food intake and body weight.
Experiment 1A: Effect on postprandial hormone levels In this experiment, we investigated the effects of OLA on the secretion of several circulating satiety/satiation factors in response to a meal. OLA was administered to rats that received a fixed amount of chow at the end of the light phase. To ensure that all rats consumed the same amount of food within a similar time-window, rats were trained in the week before treatment: each day, food was removed for the last 6 h of the light phase, at ZT11 a small portion of chow was placed in the animal's homecage and food hoppers were returned at the start of the dark phase (ZT12). On the day of treatment, food was removed at ZT6 and i.p. injections of saline (n ¼ 7) and 1 mg kg À1 OLA (n ¼ 7) were administered between ZT10 and ZT11. Half an hour after injection, rats were offered 2.3 g of chow, which they all consumed immediately. They were killed 45 min later (75 min after injection).
Experiment 1B: Effect on preprandial hormone levels In this experiment, we investigated the effect of OLA on secretion of ghrelin just prior to a meal by determining its effect just before the dark phase when rats normally initiate feeding and ghrelin levels are high. 25 The rats used in this experiment had previously been used in a study similar to experiment 2. Therefore, these rats had repeatedly experienced food deprivation for the last 6 h of the light phase, with food being replaced at the start of the dark phase. On the day of treatment, food was removed at ZT5 and rats received an i.p. injection of saline (n ¼ 7) or 1 mg kg À1 OLA (n ¼ 8) between ZT10 and ZT11. Rats were killed 45 min after drug administration, in the hour before the beginning of the dark phase.
Experiment 1C: Effect on baseline hormone levels In this experiment, we determined effects on basal ghrelin levels, by treating rats with OLA in the middle of the light phase. On the day of treatment, food was removed at ZT4 and rats received an i.p. injection of saline (n ¼ 5) or 1 mg kg À1 OLA (n ¼ 6) between ZT6 and ZT7. They were killed by decapitation 45 min after drug administration.
Collection of blood and tissues After rats were killed by decapitation, trunk blood was collected and immediately placed on ice. For experiment 1A, tubes collecting samples for CCK measurement contained approximately 12 mmol of EDTA and 75 mg aprotinine per ml blood. Tubes used to collect samples for other hormone measurements contained approximately 12 mmol ml À1 of EDTA, 75 mg ml À1 of aprotinine and 10 ml ml À1 DPP IVinhibitor (Millipore, Remecula, CA, USA). For experiment 1B and 1C, lithium-heparin-containing tubes were used with approximately 12 mmol of EDTA and 75 mg aprotinine per ml of blood. After centrifugation, plasma was stored at À20 1C until further analysis. To confirm that adiposity levels were equal between treatment groups of each experiment, epididymal and s.c. fat pads were dissected and weighed, and leptin levels determined in all plasma samples.
Experiment 2: Effect on CCK sensitivity
In this experiment, we examined the effects of OLA on CCK sensitivity in 23 rats equipped with an i.p. cannula. On test days, access to food was blocked during the last 6 h of the light phase and olanzapine (OLA) (1 mg kg
À1
) or saline was administered via the i.p. cannula between 45 and 30 min before onset of the dark phase. Half an hour later this was followed by administration of CCK-8 (3 mg kg À1 ) or PBS. Access to food was restored 5 min after a rat had received its second injection, which was always within the last 15 min of the light period. The size of the first meal ingested after food was returned was used to determine the effects of drug administration. Each rat received four combinations of injections in a Latin square design (saline/PBS, OLA/PBS, saline/CCK and OLA/CCK) and served as its own control, allowing a minimum of 2 days between test days. Unfortunately, not all i.p. canulas maintained proper function during the experiment. In these cases, administration of each drug combination was performed using regular i.p. injections.
Plasma analysis
The serine-3-acetylated form of ghrelin is considered to be responsible for the majority of its biological activities and is often referred to as 'active ghrelin'. 26 However, the total amount of ghrelin present in the circulation consists largely of the unacetylated form. 27 In the present study, effects of OLA on levels of both active and total ghrelin were determined. Levels of insulin, active ghrelin, GLP-1 (active), PYY (total) and amylin (active) were measured using a commercially available luminex kit (Milliplex rat gut hormone panel kit, 
Data analysis
Body weight, food and water intake were measured daily. Meal patterns were determined using data collected by Scales (Department of Biomedical Engineering, UMC Utrecht, The Netherlands), a program that records the weight of food hoppers in the home cage automatically every 12 s. A meal was defined as an episode of food intake with a minimal consumption of 1 kcal (0.3 g chow) and a minimal intermeal interval of 5 min. 16 The intra-abdominal transmitters sent digitized data of body core temperature (1C) and locomotor activity (arbitrary units) to a receiver plate present below the home cage via radio frequency signals. These data were automatically recorded every 10 min using DSI software (Data Science International, St Paul, MN, USA) and averaged per hour for statistical analysis. Statistical analysis was performed using SPSS15.0 (Windows). For plasma levels of different hormones in experiment 1, Mann-Whitney tests were used to determine statistical significance. To determine statistical significance between the effects of different treatment combinations on meal size in experiment 2, repeated-measures analysis of variance (ANOVA) was performed, followed, where appropriate, by paired samples t-tests. Planned pairwise comparisons were saline/PBS vs all three treatment combinations and OLA/PBS vs OLA/CCK treatment. To determine the main effects of drug treatment, as well as interaction effects, a repeated-measures two-way ANOVA was performed, with each drug as a separate within-subjects factor.
To determine the effects of OLA on locomotor activity and body temperature, a repeated-measures three-way ANOVA was performed for 24 h after injection, with both drugs and time as separate within-subjects factors. This was followed by two-way ANOVAs for different time points, where appropriate. If the condition of sphericity was not met, Greenhouse-Geisser correction was used. Findings were considered statistically significant if Po0.05 (two-tailed). Table 1 shows plasma concentrations of gastro-intestinal hormones that were determined in OLA-and saline-treated rats after they had received a fixed amount of chow at the end of the light phase (experiment 1A). No significant effects were found on postprandial levels of CCK, GLP-1, PYY and insulin, although levels of amylin tended to be increased (Z ¼ À1.85, P ¼ 0.064). Furthermore, postprandial levels of active ghrelin were B88% higher in OLA-treated rats compared with controls (Z ¼ À1.98, P ¼ 0.048). Levels of total ghrelin after a meal also tended to be increased by B10% in OLA-treated rats (Table 2 ; Z ¼ À1.72, P ¼ 0.083).
Results
Experiment 1
When ghrelin levels were measured in rats just prior to receiving their food at the end of the light phase (experiment 1B), levels of active ghrelin in OLA-treated rats were significantly higher (B104%) than in controls (Table 2 ; Z ¼ À2.32, P ¼ 0.02). Levels of total ghrelin were also higher (B27%) compared with controls (Table 2 ; Z ¼ À2.31, P ¼ 0.021). In contrast, when OLA was administered in the Olanzapine's effects on meal-related ghrelin and CCK EM van der Zwaal et al middle of the light phase (experiment 1C), active and total ghrelin levels were not significantly affected ( Table 2 ). The ratio of active to total ghrelin was not significantly different between OLA-treated rats and controls in any of the experiments (data not shown). No significant differences in leptin levels were observed between the treatment groups of each experiment (Table 2) . Furthermore, subcutaneous and epididymal white adipose tissue weights were also comparable (data not shown). This confirmed that, concerning adiposity levels, treatment groups were comparable within the experiments.
Experiment 2: Meal size
In this experiment, we investigated the effects of pretreatment with OLA or saline on the efficacy of CCK to reduce meal size at the end of the light phase. Repeated-measures ANOVA revealed a significant effect of treatment on meal size (Figure 1; F(3,66) ¼ 32.7, Po0.001). Post-hoc tests revealed that after saline pretreatment, administration of CCK (3 mg kg
À1
) caused a decrease in meal size compared with PBS injection (Po0.001). Conversely, when OLA pretreatment (1 mg kg À1 ) was followed by PBS injection, meal size was increased compared with saline/PBS treatment (Po0.001). When OLA pretreatment (1 mg kg
) was followed by CCK, meal size was increased compared with saline/PBS treatment (P ¼ 0.014) and saline/CCK treatment (Po0.001), but it was significantly lower than after OLA/PBS treatment alone (P ¼ 0.006), which suggested that CCK still had an effect on meal size. To determine whether there was any interaction between the two treatments, a two-way repeated-measures ANOVA was performed. This revealed a significant main effect of olanzapine treatment (F(1,22) ¼ 66.6, Po0.001) and of CCK treatment (F(1,22) ¼ 19.1, Po0.001), but no significant interaction (F(1,22) ¼ 0.62, P ¼ 0.44). Thus, the effect of CCK was similar for both saline and OLA pretreatment conditions. Experiment 2: Locomotor activity and body temperature OLA treatment had a significant main effect on locomotor activity (F(1,20) ¼ 32.9, Po0.001), as did time (F(23, 460) ¼ 41.8, Po0.001), whereas CCK had no effect (Figure 2a ). Interactions were only significant between time and OLA treatment (F(23, 460) ¼ 3.31, Po0.001), which was explained by the finding that activity levels were significantly lower in OLA-treated rats from the first until the fourth hour of the dark phase only (Po0.05).
Repeated-measures analysis of body core temperature revealed a significant main effect of time (F(23,460) ¼ 86.95, Po0.001) and OLA treatment (F(1,20) ¼ 8.37, P ¼ 0.009) but not of CCK treatment. The interaction between time and OLA treatment was also significant (F(23,460) ¼ 19.62, Po0.001). Interestingly, the temperature of OLA-treated rats was lower in the first 6 h (Pp0.05), whereas it was higher in the last hours of the dark phase (Po0.05, except ZT23: P ¼ 0.055). This increase in body temperature persisted at all but one time point in the following light phase (Po0.05, Figure 2b ), but disappeared after the next lights-off (data not shown).
Discussion
In this study, we investigated the effect of acute administration of OLA on several meal-related parameters in rats to gain insight into the effect of OLA on food intake. In rats treated with OLA both preprandial and postprandial ghrelin levels were increased compared with controls. Furthermore, Olanzapine's effects on meal-related ghrelin and CCK EM van der Zwaal et al in our behavioral paradigm, acute administration of OLA caused an increase in meal size, and this effect was able to counteract the satiating effect of CCK when drugs were coadministered.
In the rats that were about to initiate their night-time feeding episode, acute administration of OLA caused an increase in both active and total ghrelin levels (experiment 1B). Furthermore, in rats that had eaten a fixed amount of food at the end of the light phase, OLA also caused a significant increase in active ghrelin levels and tended to increase total ghrelin levels (experiment 1A). Conversely, when OLA was administered in the middle of the light phase, when rats hardly eat, it failed to affect ghrelin levels (experiment 1C). Together, these findings indicate a selective effect of OLA on meal-related ghrelin secretion. Measurement of postprandial levels of several gastro-intestinal hormones in rats that had eaten a fixed amount of food (experiment 1A) indicated that OLA does not reduce the secretion of any of these satiating factors. As we only analyzed plasma levels at one time point, we cannot exclude an effect of OLA occurring at an earlier or later time. However, both our findings are in line with a recent clinical study in healthy volunteers in which the authors reported an increase in total ghrelin levels at dinner time after 8 days of OLA treatment, but no reductions in the levels of CCK, PP, PYY and GLP-1. 28 In patients, increased levels of ghrelin have also been reported, especially after long-term treatment with OLA. [29] [30] [31] [32] Furthermore, when BMI was taken into account, ghrelin levels of chronically treated patients were higher than would be expected for an untreated patient with the same BMI. 30, 32 As ghrelin levels are known to be influenced by obesity levels, 33 this indicates that the effect of OLA on ghrelin levels is independent of weight gain. Nevertheless, clinical findings are not entirely consistent, as other authors have reported decreased levels of ghrelin, [34] [35] [36] [37] [38] especially after short-term treatment with OLA.
Little is known about the regulation of peripheral ghrelin secretion, and the mechanisms underlying the effect of OLA on peri-prandial ghrelin levels, therefore, remain unclear. However, increased ghrelin levels were also reported in rats receiving an injection of clozapine, an antipsychotic closely related to OLA, and after administration of an alphaadrenergic receptor antagonist. 39 This suggests that the effects of clozapine and OLA may be due to their antagonistic effect at adrenergic receptors. 40 The effect of acute administration of OLA on meal size in the behavioral paradigm used in this study replicates our findings with continuous administration of OLA, which confirms that the paradigms are comparable. 16 Moreover, it is in line with the findings of other authors. [13] [14] [15] The increase in peri-prandial ghrelin levels by OLA may partially underlie this effect. As mentioned earlier, in the study by Date et al., 22 ghrelin pretreatment was able to completely abolish the effect of CCK, indicating a reduction in CCK sensitivity by ghrelin. However, we failed to observe a significant interaction between OLA and CCK treatment, which suggests functional antagonism instead of a direct effect on CCK sensitivity. A possible explanation for this may be that ghrelin levels in the present study were not high enough to completely block the effect of CCK. In the study by Date et al., the effect of CCK on food intake was abolished by pretreatment with 3 nmol (B10 mg) ghrelin intravenous in 8-h fasted rats, and a dose of 1.5 nmol (B5 mg) was shown to prevent a CCK-induced increase in vagal firing. 22 Both these doses are likely to have resulted in much higher ghrelin levels than observed in the present study. 41 Furthermore, although the minimum effective dose of ghrelin to affect vagal firing was 0.3 pmol (B1 ng), the study of Date et al.
22
did not report whether this lower dose was also sufficient to block the effect of CCK. Therefore, it is possible that CCK sensitivity is not as clearly affected by lower levels of ghrelin, although these doses of ghrelin might still affect feeding through other pathways. Indeed, the observation that OLA did not significantly reduce CCK sensitivity in the present study suggests that the increase in meal size caused by OLA is most likely determined by pathways that are largely independent of CCK. It is known that neuropeptide Y neurons in the arcuate nucleus of the hypothalamus are activated by both peripheral and central administration of ghrelin 42, 43 and that central administration of neuropeptide Y is able to counteract the satiating effect of peripheral CCK administration. 44 Therefore, it is possible that the elevation in ghrelin levels by OLA activated NPY neurons, which thereby counteracted the effects of CCK. This possibility is supported by a recent study that observed increased NPY mRNA levels after acute administration of OLA. 45 However, the administered dose was very high (10 mg kg
À1
), and other studies administering a lower dose subchronically failed to observe effects on levels of NPY mRNA levels. 14, 46 Therefore, it remains to be determined whether OLA affects NPY levels at the dose used in the present study. Finally, it should be noted that, in addition to ghrelin and CCK, many other factors have a role in meal termination and may therefore be involved in the effect of OLA on food intake, including the response to hormones such as leptin, insulin, GLP-1 and PYY. 11, 12 Additional experiments are necessary to determine the effect of OLA on the sensitivity to other hormones and peptides.
In addition to the effect on meal size, acute administration of OLA also caused a (temporary) reduction in locomotor activity and body core temperature, which is similar to previous observations. 16, [47] [48] [49] [50] Interestingly, the decrease in body temperature was followed by a much longer-lasting increase in temperature, which continued into the following light phase. Reactive hyperthermia was previously also reported after OLA was discontinued in rats that had been treated continuously for 18 days. 51 Our data indicate that such a compensatory response can already occur after a single injection of OLA.
Olanzapine's effects on meal-related ghrelin and CCK EM van der Zwaal et al Taken together, this study used a paradigm of acute OLA administration in rats to investigate the mechanisms underlying the effects of OLA on food intake. It shows that administration of this drug leads to an increase in peri-prandial ghrelin levels and this effect may partially underlie the finding that OLA counteracts the satiating effect of CCK.
